Ortho Clinical Diagnostics - a Johnson & Johnson Company.

Global Sites:  Canada (English)

Skip navigation links
    
Solutions that drive knowledge. Solutions that drive knowledge.

Solutions that drive knowledge.


Clinical Laboratories | VITROS® Menu

 

 

VITROS® Menu

 

 

Ortho Clinical Diagnostics is committed to constantly evaluating our assay portfolio to bring you a broad disease state menu that meets your testing needs and helps doctors and patients know more so treatment decisions can be made sooner.

 

Our menu covers 90% of the menu needs and 99% of the testing volume for typical labs with:

 

Over 120 available assays


10 user-defined chemistry channels


Wide accessible menu on-board at all times


Standardized reagents and results across all VITROS® platforms

 

World-class assays for quality results

 

VITROS® DAT Assays

Excellent correlation to EMIT® and greater precision increase confidence in patient results. Allows consolidation with routine chemistry.

 

VITROS® Troponin I ES Assay

Improved sensitivity delivers reliable information for patients with acute coronary syndrome. Meets ACC/ESC guideline for acceptable imprecision in a high sensitivity assay (10% CV at 99th percentile).

 

VITROS® NT-proBNP Assay

Provides confidence to physicians for the differential diagnosis of heart failure, improving patient care. Enables consolidated cardiac testing on one fully random-access system. Adopted in ESC/ACC/AHA practice guidelines.1,2

 

VITROS® d%A1C Assay

High-quality results with traceability to the NGSP and IFCC Standards. No manual pre-treatment means fewer potential errors.

  

VITROS® TSH 3rd Generation Assay

Third generation sensitivity means this assay can be used as a front-line screen that enables cost-effective algorithmic testing stratetgies.3,4,5,6 Smaller sample volume minimizes costs and operator intervention.

 

VITROS® Free T4 Assay

Correlates with Equilibrium Dialysis (ED), considered the “Gold Standard” for free hormone analysis.7,8 Not impacted by serum protein concentrations allowing for better differentiation of non-thyroidal illness.

 

VITROS® ß-hCG II

Wide dynamic range and equivalent results in serum and plasma minimize dilutions, provide flexibility and improve turnaround time.

 

VITROS® Anti-HCV Assay

A version 3.0 fully automated, random-access diagnostic test for IgG antibody to hepatitis C virus. Provides improved sensitivity. Results in less than 60 minutes, available any time in any order.

 

VITROS®  Electrolytes (Na+, Cl- and K+)

World-class Direct Ion Selective Electrodes (ISEs) with true results regardless of dilution, interferents or presence of abnormal proteins or lipids—all with lower overall costs.

 

VITROS®  BuBc Assay

World-class Bilirubin results with direct BuBc measurement correlated to HPLC, high specificity and small sample volume, ideal for neonatal populations.

 

Chemistry

Acid Phos

Albumin

Alcohol

Alk Phos

ALT

Ammonia

Amylase

AST

BuBc Bilirubin

BUN

Calcium

Carbon Dioxide

Chloride

Cholesterol

Cholinesterase

CK

CK-MB

Creatinine

CSF Protein

dHDL

dLDL

dTIBC

GGT

Glucose

Iron

Lactate

LDH

Lipase

Magnesium

Phosphorus

Potassium

Sodium

Total Bilirubin

Total Protein

Triglycerides

TIBC

Uric Acide

Urine Protein

TDM

Caffeine

Carbamazepine

Digoxin

Gentamicin

Lithium

Phenobarbital

Phenytoin

Theophylline

Tobramycine

Valproic Acid

Vancomycin

 

DAT & Toxicology

Acetaminophen

Alcohol

Amphetamines

Barbiturates

Benzodiazepines

Cocaine Metabolite

Methadone

Opiates

Phencyclidine

Salicylate

THC

 

Metabolic

Homocysteine

% Hemoglobin A1c

Cortisol (S&U)

NTx

Intact PTH**

 

Prenatal

AFP*

Free B-hCG*

 

Women's Health

Preeclampsia**

Proteins

α-1-antitrypsin

Apo A1

Apo B

ASO

C3

C4

CRP

hsCRP

Haptoglobin

IgA

IgG

IgM

Microalbumin

Prealbumin

RF

Transferrin

 

Cardiology

CK-MB

Troponin I ES

Myoglobin

NT-proBNP

 

Oncology

Total PSA

CEA

AFP

CA 125 IITM

CA 15-3TM

CA 19-9TM

 

Thyroid

Free T4

Free T3

Total T4

Total T3

TSH 3rd Gen

T3 Uptake

Anemia

Ferritin

B12

Folate

RBC Folate

 

Endocrine

Total B-hCG II

Estradiol

Progesterone

Testosterone

LH

FSH

Prolactin

 

Infectious Disease#

HBsAg

HBsAG Confirmatory

HBsAG ES**

Anti-HBs

Anti-HCV

Anti-HBc

Anti-HBc IgM

HBeAg*

Anti-HBe*

Anti-HAV Total

Anti-HAV IgM

Anti-HIV 1+2

HIV Ag/Ab Combo**

Toxoplasma IgG*

Toxoplasma IgM*

Rubella IgG

Rubella IgM*

CMV IgG*

CMV IgM*

 

Diabetes

Glucose

% Hemoglobin A1c

Pre-Diabetes Diagnostic**

 

 

* Not approved or cleared for U.S. market

** In development

# HIV and Hepatitis co-developed with Novartis Vaccines and Diagnostics Inc.

 

PSA, CA125II, CA 15-3, CA 19-9 are tradmarks of Fujirebio Diagnostics, Inc.

 

Product availability subject to local regulatory requirements.

 

Note: Please consult your Ortho Clinical Diagnostics Sales Representative for the optimal VITROS® System solution to accommodate your specific menu needs. Product availability subject to local regulatory requirements.

 

 

1. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart Journal. 2001;22:1527-1560.

 

2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of

chronic heart failure in the adult. Circulation. 2005;112:e154-e235.

 

3. Demers LM, Spencer CA. The National Academy of Clinical Biochemistry LaboratoryMedicine Practice Guidelines, Published Guidelines; Laboratory support for thediagnosis and monitoring of thyroid disease. 2002(13). http://www.aacc.org/sitecollectiondocuments/nacb/lmpg/thyroid/thyroidfullversionwithcover.pdf. Accessed on July 18, 2008.

 

4. Stockigt J. Chapter 6B: Clinical strategies in the testing of thyroid function. In: Thyroid Disease Manager. 2004.

http://www.thyroidmanager.org/Chapter6/6b-frame.htm. Accessed on July 18, 2008.

 

5. Spencer, CA; Thyroid Profiling for the 1990s; Free T4 Estimate or Sensitive TSH Measurement. J Clin Immunology. 1989;12:82-89.

 

6. Nicoloff JT, Spencer CA; Clinical Review 12; The use and misuse of the sensitive thyrotropin assays. J Clin Endocrinol Metab. 1990;71:553-558.

 

7. Christofides ND, Wilkinson E, Stoddart M, Ray DC, Beckett, GJ. Assessment of serum thyroxine binding capacity-dependent biases in free thyroxine assays. Clin Chem. 1999;45(4):520-5.

 

8. Sapin R, Schlienger JL, Gasser F, et al. Intermethod discordant free thyroxine measurements in bone marrow-transplanted patients. Clin Chem. 2000;46(3):418-22.

 


© Ortho-Clinical Diagnostics, a division of Janssen-Ortho Inc. 2003-2010 This site is published by Ortho Clinical-Diagnostics, a division of Janssen-Ortho Inc, which is solely responsible for its contents. Product availability is subject to fulfillment of regulatory requirements in each market. This site was written for healthcare professionals in Canada only.
Last Modified Date:03/11/2009 09:04